MKMatthias Kögel

Matthias Kögel

*This is an algorithmically generated author record based on publicly available information.

Matthias Kögel has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Eribulin-Induced Peripheral Neuropathy in Locally Advanced or Metastatic Breast Cancer: Final Analysis of the Prospective Cohort IRENE Study

    by Marcus Schmidt, Tobias Hesse, Oliver Hoffmann, Bernhard J. Heinrich, Tjoung-Won Park-Simon, Eva-Maria Grischke, Rudolf Weide, Harald Müller Huesmann, Kerstin Lüdtke-Heckenkamp, Dorothea Fischer, et al.

    Eribulin is a preferred treatment for patients with advanced breast cancer (BC) following anthracyclines and taxanes. The final analysis of the IRENE study assessed the incidence and resolution of eribulin-induced peripheral neuropathy (EIPN), along with safety and quality of life (QoL), in patients with advanced/metastatic BC. IRENE was an observational, single-arm, prospective, multicenter cohort study. Patients aged ≥18 years with locally advanced/metastatic BC that progressed after 1–3 prior chemotherapeutic regimens received eribulin and were monitored for new-onset or worsening EIPN. Secondary endpoints included time to disease progression, safety, and health-related QoL. In total, 108 (32.2%) out of 335 patients experienced EIPN; 18 (5.4%) experienced grade ≥3 EIPN. Median time to EIPN resolution (EIPN ended or returned to baseline) was 78.7 weeks (95% CI 77.1—not estimable). Median time to disease progression was 4.5 months (95% CI 3.9–5.5). Treatment-emergent adverse events (TEAEs) occurred in 322 (96.1%) patients; serious TEAEs occurred in 185 (55.2%) patients. Incidence and resolution rates of EIPN were comparable with existing evidence from previous trials. TEAEs were consistent with the established eribulin safety profile, with no new safety signals. Eribulin treatment did not appear to affect QoL, as measured by EQ-5D-3L and EQ-VAS, or patient-reported neuropathy symptoms, as measured by the PNQ.


  • Open Access

    Eribulin-Induced Peripheral Neuropathy in Locally Advanced or Metastatic Breast Cancer: Final Analysis of the Prospective Cohort IRENE Study

    by Marcus Schmidt, Tobias Hesse, Oliver Hoffmann, Bernhard Heinrich, Tjoung-Won Park-Simon, Eva-Maria Grischke, Rudolf Weide, Harald Müller Huesmann, Kerstin Lüdtke-Heckenkamp, Dorothea Fischer, et al.

    Eribulin is a preferred treatment for patients with advanced breast cancer (BC) following anthracyclines and taxanes. The final analysis of the IRENE study assessed the incidence and resolution of eribulin-induced peripheral neuropathy (EIPN), along with safety and quality of life (QoL), in patients with advanced/metastatic BC. IRENE was an observational, single-arm, prospective, multicenter, cohort study. Patients aged ≥18 years with locally advanced/metastatic BC that progressed after 1-3 prior chemotherapeutic regimens received eribulin and were monitored for new-onset or worsening EIPN. Secondary endpoints included time to disease progression, safety, and health-related QoL. 108 (32.2%) Of 335 patients experienced EIPN; 18 (5.4%) experienced grade ≥3 EIPN. Median time to EIPN resolution (EIPN ended or returned to baseline) was 78.7 weeks (95% CI 77.1-not estimable). Median time to disease progression was 4.5 months (95% CI 3.9-5.5). Treatment-emergent adverse events (TEAEs) occurred in 322 (96.1%) patients; serious TEAEs occurred in 185 (55.2%) patients. Incidence and resolution rates of EIPN were comparable with existing evidence from previous trials. TEAEs were consistent with the established eribulin safety profile, with no new safety signals. Eribulin treatment did not appear to affect QoL, as measured by EQ-5D-3L and EQ-VAS, or patient-reported neuropathy symptoms, as measured by the PNQ.

  • Verlauf eines frühgeborenen Geminus nach totalem Muttermundsverschluss bei Spontanabort des ersten Geminus in der 19+1 Schwangerschaftswoche – Fallbericht und Literaturübersicht

    by Matthias Kögel, Matthias Werner, Markus Knuf, Thomas Hitschold

    Zusammenfassung: Wir berichten über den geburtshilflichen und neonatologischen Verlauf einer 34-jährigen Geminigravida, die sich erstmalig in der 16+1 Schwangerschaftswoche (SSW) in unserer Klinik mit vorzeitigem Blasensprung vorstellte. Bei vitalen und zeitgerecht entwickelten Gemini mit Anhydramnion des führenden Zwillings erfolgte die stationäre Überwachung unter intravenöser antiinfektiver Therapie. Nach verhaltenem Abort des ersten Geminus in der 19+1 SSW wurde eine operative Intervention mit assistierter Entbindung des ersten Geminus unter Belassung der Plazenta in situ mit anschließendem notfallmäßigem totalen Muttermundverschluss durchgeführt. Die verbliebene Einzelschwangerschaft konnte bis zur 24. SSW fortgeführt werden. Dann erfolgte bei unaufhaltsamer Wehentätigkeit, vorzeitigem Blasensprung und steigenden Entzündungszeichen im Labor der Mutter die eilige Sectio. Postnatal zeigte das Frühgeborene einen für das Gestationsalter insgesamt erfreulichen Verlauf, so dass in zukünftigen ähnlichen Fällen die Option der operativen Maßnahmen mit berücksichtigt werden sollte.

  • Akute Komplikation mit Schocksymptomatik bei elektiver Sectio caesarea

    by Maria Kögel, Matthias Kögel, A. Klee, M. Gonser